In the non-alcoholic steatohepatitis (NASH) space, Novo Nordisk was the star of the 2024 American Association for the Study of Liver Disease meeting with additional data from its Phase III study of semaglutide in NASH, but Boston Pharmaceuticals and Viking Therapeutics appear to have gained momentum in the R&D race while the field is also looking ahead to expected data in February for Akero’s candidate in cirrhotic NASH patients.
NASH Updates: Boston Pharma, Viking Line Up As Serious Competitors
New Data Coming Out Of AASLD
Boston Pharma may be rising in the FGF21 space, while Viking could be formidable competition for Madrigal in the THRβ agonist class. Akero will soon report potentially groundbreaking data in cirrhotic NASH.
More from Conferences
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.
• By
Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.
• By
CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.